Masimo has been granted a patent for an oximeter system that aims to improve the accuracy of perfusion index measurements. The system uses a baseline measurement and multiple calculations to reduce errors and provide a more reliable indication of perfusion index. GlobalData’s report on Masimo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Masimo, Medical data analysis was a key innovation area identified from patents. Masimo's grant share as of September 2023 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for smoothing perfusion index measurement using baseline
See Also:
A recently granted patent (Publication Number: US11759130B2) describes an oximeter system and a patient monitor system that utilize multiple techniques to determine the perfusion index, which is an indication of blood flow in body tissue.
The oximeter system includes an input for receiving intensity signal data from a detector that detects light attenuated by body tissue. A processor is configured to determine pulse information from the intensity signal data and then calculate two indications of amplitude data using different techniques. The final indication of amplitude data is determined by selecting the lowest indication, averaging the two indications, or using a statistical analysis. This final indication is then outputted as the perfusion index.
The second technique mentioned in claim 2 is based on a combination of pulses, while claim 3 states that the final indication can be determined based on a signal quality indication. Claim 4 specifies that the lowest indication of amplitude can be selected to determine the final indication, while claim 5 suggests averaging the two indications. Claim 6 mentions the use of statistical analysis to determine the final indication.
The patient monitor system, described in claims 9-17, also calculates multiple indications of perfusion index based on pleth data using different calculation techniques. The final indication is determined based on signal quality, the lowest value of the indications, an average of the indications, or a statistical analysis. Claim 10 specifies that one of the calculation techniques performs analysis on a pulse by pulse basis. Claim 11 states that the final indication can be determined using a signal quality indication, while claim 12 mentions the use of amplitude data. Claims 13 and 14 describe the amplitude data as the maximum and minimum amplitude of one or multiple pulses. Claim 15 specifies selecting the lowest indication of amplitude, claim 16 suggests averaging two indications, and claim 17 mentions the use of statistical analysis.
Overall, these systems utilize various techniques and calculations to determine the perfusion index, providing valuable information about blood flow in body tissue. The patent aims to improve the accuracy and reliability of perfusion index measurements, which can be beneficial in medical monitoring and diagnosis.
To know more about GlobalData’s detailed insights on Masimo, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
